Beam Therapeutics Inc. (BEAM) Cash Flow Statement

The OCF-to-net-income ratio clusters near 0.8 to 0.9 in most quarters, which suggests that the bulk of the reported loss reflects real cash consumption rather than accrual distortion. The 2025Q4 net income of $244.3M paired with operating cash flow of -$83.3M shows the disconnect that a non-operating gain can create, and it warrants caution in reading headline earnings. Investors should monitor whether future net income is again driven by non-operating items rather than core collaboration performance.

The extreme swing in FCF margin reflects the lumpy nature of collaboration revenue relative to a fixed R&D base, rather than any improvement in unit economics. Because capital expenditure is minimal in absolute terms, the cash drain is driven almost entirely by operating spend. The trajectory suggests that funding needs will continue to depend on balance sheet reserves and external capital until revenue recognition becomes more recurring.

The absence of dividends and repurchases is consistent with a company whose cash flow is consumed by clinical development. Capital deployment is therefore entirely internal, focused on sustaining R&D rather than returning value. This structure suggests that shareholder value depends on clinical milestones rather than near-term cash distributions.